Q1 Financials; Wee1i Data Ahead at ASCO

Research evidence excerpt

Q1 Financials; Wee1i Data Ahead at ASCO

Company Report

May 13, 2026 Aprea Therapeutics, Inc. (APRE)

Rating: Q1 Financials; Wee1i Data Ahead at ASCOOUTPERFORM

Price:

$0.87 The Wedbush View

12-Month Price Target:

$6.00 (from $7.00) APRE reported first quarter financials and provided corporate updates ahead

of ACESOT-1051 data at the ASCO 2026 Annual Meeting on May 30th. As a

Analysts reminder, the ACESOT-1051 trial is currently investigating monotherapy APR-1051

Robert Driscoll, Ph.D. in patients uterine serous carcinoma, CCNE1 overexpressed PROC, CRC harboring

(415) 274-6863 KRAS and TP53 mutations, HPV+ HNSCC, as well as additional solid tumors

Robert.Driscoll@wedbush.com harboring mutations in CCNE1, CCNE2, PPP2R1A, or FBXW7; dose escalation

Geoffrey Von Der Ahe remains ongoing, with APRE currently enrolling DL9 (300 mg QD), as well as backfill

(628) 223-0517 cohorts at the 220 mg dose level). Further, the company is currently launching ageoffrey.vonderahe@wedbush.com

50-patient expansion cohort investigating APR-1051 in patients with USC or cyclin

E1 overexpressed PROC, potentially informing a development path forward in the

Company Information indications; APRE plans on completing dose escalation in 2Q:27. To date, two

Market Cap (M) $13 patients have reported PRs, one uterine carcinosarcoma and one USC patient, both

Shares Outst (M) 14.7 harboring PPP2R1A mutations, treated at the 220 mg QD and 150 mg QD doses,52-Week Range $0.55 - $2.22

respectively. Further, the WEE1 inhibitor has been generally well tolerated to date,

REV (M) in $ with no limiting toxicities, and most AEs being G1/2 nausea and fatigue. Regarding

FYE Dec 2024A 2025A 2026E ATR inhibitor ATRN-119, APRE announced wind-down of ABOYA-119, investigating

Q1 Mar 0.4A 0.2A 0.3A